New Drug Application (NDA) submission on track for January 2026NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: ...

Drivers with sleep conditions including sleep apnoea, narcolepsy and cataplexy must inform the DVLA or risk a fine of up to ...

SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...

Cataplexy is a sudden, brief loss of voluntary muscle tone triggered by strong emotions such as laughter, excitement, anger or fear. There is a strong association between cataplexy and narcolepsy, a ...

OBJECTIVE: Narcolepsy (with and without cataplexy) and idiopathic hypersomnia, are disorders with common features but with different HLA-DQB1*0602 allele prevalence. The present study describes the ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, ...

An investigational oral selective orexin receptor 2 agonist (oveporexton, Takeda) demonstrated significantly improved measures of wakefulness, sleepiness, and cataplexy in a phase 2b study of adults ...

Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain. In this phase 2, randomized, placebo-controlled trial, ...

SAN DIEGO — The investigational drug AXS-12 (reboxetine, Axsome Therapeutics) is safe and effective for the treatment of cataplexy (emotionally induced muscle weakness) and excessive daytime ...

"Here's How I Knew I Had a Brain Tumor": One Survivor's Story After a Common Complaint Became Too Much Narcolepsy: What Doctors Wish You Knew About This Sleep Disorder "Here's How I Knew I Had ...

Once a controversial European depression treatment that never made it to the U.S. market, reboxetine may soon see new life under Axsome Therapeutics' stewardship. Since collecting the exclusive U.S.

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...